Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
Collegium Pharmaceuticals, Inc. received an updated ownership report from Eventide Asset Management and related individuals. As of December 31, 2025, Eventide and its affiliates reported beneficial ownership of 1,876,239 shares of Collegium common stock, representing 5.9% of the outstanding shares.
Eventide holds sole voting and dispositive power over these shares, while Finny Kuruvilla and Robin C. John report shared voting and dispositive power over the same 1,876,239 shares. The position is held through registered funds and separately managed accounts, with no single account owning more than 5% of the company’s stock.
The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Collegium. They also formally disclaim beneficial ownership beyond what is required for reporting under beneficial ownership rules.
Pharmaceutical, Inc. executive vice president and general counsel David Dieter reported several equity compensation transactions. He acquired 22,194 restricted stock units at $0 and 9,005 performance share units after performance goals were confirmed, also at $0. To cover tax withholding on vested performance units, 2,781 shares were disposed of at $46.75. After these transactions, he directly owned 97,271 shares of common stock. The new RSUs vest one-third on February 10, 2027, with the remainder vesting in equal annual installments over the following two years, contingent on his continued service.
Pharmaceutical, Inc.'s President, CEO and director Vikram Karnani reported equity compensation transactions in the company’s common stock. On February 10, 2026, he received a grant of 79,264 restricted stock units, each representing one future share, at a price of $0 per share.
On the same date, 32,531 performance share units from the 2025 fiscal year vested after performance criteria were met, increasing his direct holdings. The company withheld 11,296 shares at $46.75 per share to cover tax obligations tied to the vesting, leaving Karnani with 197,864 shares of common stock owned directly after these transactions.
Pharmaceutical, Inc.’s EVP and Chief Medical Officer Thomas B. Smith reported equity compensation changes on February 10, 2026. He received 14,268 restricted stock units with no cash paid and 22,774 performance share units that vested after performance goals were certified.
One-third of the new RSUs will vest on February 10, 2027, with the rest vesting in equal annual installments over the next two years, subject to continued service. To cover withholding taxes on the PSU and RSU vesting, 5,897 and 11,538 shares, respectively, were withheld at $46.75 per share, leaving him with 90,651 common shares owned directly.
Pharmaceutical, Inc. Executive Vice President and Chief Financial Officer Colleen Tupper reported equity compensation activity in common stock. On February 10, 2026, she acquired 26,421 restricted stock units and 32,734 performance share units at no cost, reflecting new stock-based awards and vesting.
To cover tax withholding on these vestings, 11,861 shares and 26,679 shares were withheld at a price of $46.75 per share rather than sold in the open market. After these grant, vesting, and withholding transactions, she directly beneficially owned 147,282 shares of common stock.
Pharmaceutical, Inc.'s EVP & Chief Commercial Officer Scott Dreyer reported equity awards and related tax withholding transactions in common stock on February 10, 2026. He acquired 19,023 restricted stock units and 30,702 performance share units at a stated price of $0 per share.
The performance share units reflect previously granted awards that vested after performance criteria were met. The company withheld 9,977 and 21,615 shares at $46.75 per share to cover tax obligations on these vestings. After these grants and withholdings, Dreyer directly owned 121,746 shares of common stock.
Collegium Pharmaceutical, Inc. reported that it has issued full-year 2026 guidance for revenue and adjusted EBITDA. The company disclosed this information in a press release that is furnished as an exhibit and not filed for liability purposes. It also posted a corporate presentation on its website that may be used in discussions with investors, analysts and other stakeholders, and furnished that presentation as a separate exhibit.
The company emphasized that these outlook figures and related commentary are forward-looking statements based on current management expectations and are subject to numerous risks and uncertainties. It highlighted factors such as commercialization performance of its products, market size and acceptance, reimbursement, regulatory developments, litigation, supply, financing needs and intellectual property protection as key risks that could cause actual results to differ materially from the guidance.
Collegium Pharmaceutical (COLL) Form 4: Director John A. Fallon, MD exercised options and sold shares on 11/12/2025. He exercised stock options for 15,000 shares at $16.49 and 19,853 shares at $9.33, then sold 34,853 shares at a weighted average price of $47.2136.
Following these transactions, he directly beneficially owned 64,634 shares. A footnote states the sale occurred in multiple trades between $46.805 and $47.51. The reported options were fully vested and exercisable, and the specific option positions exercised now show 0 remaining.
Collegium Pharmaceutical (COLL) reported an insider transaction by its EVP & Chief Financial Officer. On 11/06/2025, the officer sold 25,142 shares of common stock at a weighted average price of $40.3801 and a separate tranche of 4,858 shares at a weighted average price of $41.2756, totaling 30,000 shares. Following these sales, the officer beneficially owned 126,667 shares, held directly.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025, with prices executed across ranges of $40.00–$40.98 and $41.00–$41.75, as disclosed.
Collegium Pharmaceutical (COLL) reported stronger Q3 2025 results. Product revenues, net reached $209,361 (up from $159,301), and net income was $31,507 (vs. $9,335). Gross profit rose to $129,171 with total operating expenses at $67,084. Diluted EPS was $0.84.
For the nine months, product revenues, net were $575,118 (vs. $449,500) and operating cash flow was $206,275. Cash and cash equivalents increased to $150,096, with marketable securities at $135,767. By product in Q3: Belbuca $58,255; Xtampza ER $50,478; Jornay PM $41,802; Nucynta IR $31,988; Nucynta ER $22,813; Symproic $4,025. Jornay PM growth reflects the Ironshore acquisition, which contributed a $635,000 intangible asset now amortizing over 7.7 years.
Debt included term notes payable of $570,166 (carrying value) and convertible senior notes at $237,950. The deferred royalty obligation tied to Jornay PM carried $122,279, with the royalty rate stepping from 7.4% before July 1, 2025 to 9.7% thereafter through March 2032.